The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats (Q42445636)

31 October 2017

The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats (English)

1 reference

31 October 2017

0 references

0 references

0 references

1 reference

3

Raphael Mechoulam

1 reference

31 October 2017

Yossi Gilgun-Sherki

1

1 reference

PubMed ID

12899667

31 October 2017

Eldad Melamed

series ordinal

2

1 reference

PubMed ID

12899667

31 October 2017

Daniel Offen

series ordinal

4

1 reference

31 October 2017

1 August 2003

1 reference

Basic and Clinical Pharmacology and Toxicology

31 October 2017

1 reference

31 October 2017

93

1 reference

31 October 2017

2

1 reference

31 October 2017

66-70

1 reference

Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics

31 October 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Brain cannabinoid systems as targets for the therapy of neurological disorders

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Cannabinol and cannabidiol in combination: temperature, open-field activity, and vocalization

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Enantiomeric cannabinoids: stereospecificity of psychotropic activity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

A 6-hydroxydopamine-induced selective parkinsonian rat model

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Anandamide: a candidate neurotransmitter heads for the big leagues.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

Synthesis of a primary metabolite of cannabidiol

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930202.X

7 January 2021

10.1034/J.1600-0773.2003.930202.X

Identifiers

DOI

1 reference

31 October 2017

1 reference

PubMed ID

12899667